Dignified Death not Common, Doctors and Nurses Say

Publication
Article
OncologyONCOLOGY Vol 12 No 3
Volume 12
Issue 3

Of acute-care doctors and nurses responding to a national survey, 62% said that clinically hopeless patients have a “dignified death” in the hospital only “sometimes.” Another 33% said that this scenario occurs “frequently,” and just 5% said “always.”

Of acute-care doctors and nurses responding to a national survey, 62% said that clinically hopeless patients have a “dignified death” in the hospital only “sometimes.” Another 33% said that this scenario occurs “frequently,” and just 5% said “always.”

The poll was conducted in July 1997 among chief doctors and nurses in hospital acute-care units nationwide by Dignified Death Update, a monthly newsletter for health-care professionals.

Other survey results included the following:

  • In cases that are deemed “clinically hopeless,” 51% of doctors and nurses said that the patient is “frequently” or “sometimes” (10% and 41%, respectively) “eased into death by staff through unspoken agreement (ie, passive nonaction) without the explicit request of relatives.” However, 48% of respondents definitely stated that this “never” occurs.

  • “Futile last-ditch treatment” was administered “frequently” or “sometimes” in clinically hopeless cases, said 97% of respondents. Only 2% said that this was “never” done.

  • If patients have made their end-of-life instructions known prior to death (such as by a living will, advance directive, or appointment of a health-care surrogate), these instructions are followed “frequently,” replied 41% of respondents. However 32% indicated that such instructions are followed only “sometimes.”

  • Do staff on an acute-care unit end life support more quickly for hopeless cases “if the unit is already filled to capacity and new patients are waiting to be admitted?” In response to this question, 89% said that the practice “never” occurs. However, 5% said that scenario happens “sometimes,” and another 5% said that they were “not sure” whether it ever occurs.

  • The vast majority (93%) of professionals said that patients’ relatives “drag their feet” about decisions to end life support in hopeless cases. The 93% figure comprised 29% who felt relatives “frequently” procrastinated and 64% who said that this occurs “sometimes.” This survey finding was confirmed by another question that approached the same topic from the opposite direction: Asked whether patients’ relatives are “too eager to end life support,” 79% of the doctors and nurses responded “no.”

Survey Reflects “Prevailing Opinion”
The survey did not obtain a strict random sample and, thus, indicates the general direction of professional thought rather than an exact quantitation of it, said newsletter publisher, Leslie C. Norms, md, PhD. However, he added that because there were 362 responses from both large and small hospitals, because these facilities were spread across the country, and because both physician and nurse “chiefs-of-units” responded, he was confident that the survey had accurately captured current prevailing opinion in hospitals.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video